[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337803-105":59,"doc-detail-337803-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","molecular-landscape-and-clinical-implication-of-ccne1-amplified-esophagogastric-cancer","Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer","","Cyclin E overexpression driven by CCNE amplification is a key driver of genomic instability in gastric cancer, yet its clinical meaning has been unclear. Genomic, transcriptomic, and immune profiling of 7,083 esophagogastric tumors defined how CCNE amplification shapes molecular traits and treatment outcomes. CCNE amplification occurred across esophageal and gastric subtypes and was enriched at metastatic sites. It matched chromosomal instability, altered mutation patterns and immune cell composition, and showed therapy-specific survival effects.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-landscape-and-clinical-implication-of-ccne1-amplified-esophagogastric-cancer/337803/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-landscape-and-clinical-implication-of-ccne1-amplified-esophagogastric-cancer/337803.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":56},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"How was CCNE1 amplification assessed in esophagogastric tumors in this study?","Question",{"text":112,"@type":113},"The study integrated genomic, transcriptomic, and immune profiling analyses across 7,083 esophagogastric tumors to evaluate CCNE1 amplification and its associations with molecular features and outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which tumor types showed CCNE1 amplification, and how common was it?",{"text":117,"@type":113},"CCNE1 amplification was reported in 6.2% of esophageal adenocarcinoma samples, 7.0% of esophagogastric junction carcinoma, 4.2% of gastric adenocarcinoma, and 0.8% of esophageal squamous cell carcinoma.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune-related differences were found between CCNE1-amplified and nonamplified tumors?",{"text":121,"@type":113},"Although PD-L1 expression and tumor mutational burden did not differ, transcriptional immune profiling associated CCNE1 amplification with decreased B cells and increased M1 macrophages.",{"name":123,"@type":110,"acceptedAnswer":124},"How did CCNE1 amplification relate to survival after different treatments?",{"text":125,"@type":113},"Real-world survival analysis indicated worse survival after trastuzumab for HER2-positive tumors in patients with CCNE1-amplified gastric cancer, but better survival after immunotherapy.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},337803,1790165733,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":56,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-23-0496](https://doi.org/10.1158/2767-9764.CRC-23-0496)   \nMolecular Landscape and Clinical Implication of CCNE1-ampliﬁed Esophagogastric Cancer  \nNaryan Rustgi1 , Sharon Wu2 , Timothy Samec2 , Phillip Walker2 , Joanne Xiu2 , Emil Lou3 , Sanjay Goel4 , Anwaar Saeed5 , and Ryan H. Moy6  \nOPEN  \nACCESS  \nCheck for updates  \nABSTRACT  \nCyclin E overexpression as a result of CCNE􀀂 amplification is a critical driver of genomic instability in gastric cancer, but its clinical implication is largely unknown. Thus, we integrated genomic, transcriptomic, and immune profiling analysis of 7,083 esophagogastric tumors and investigated the impact of CCNE􀀂 amplification on molecular features and treatment outcomes. We identified CCNE􀀂 amplification in 6.2% of esophageal adenocarcinoma samples, 7.0% of esophagogastric junction carcinoma, 4.2% of gastric adenocarcinoma samples, and 0.8% of esophageal squamous cell carcinoma. Metastatic sites such as lymph node and liver showed an increased frequency of CCNE􀀂 amplification relative to primary tumors. Consistent with a chromosomal instability phenotype, CCNE􀀂 amplification was associated with decreased CDH􀀂 mutation and increased TP􀀃􀀄 mutation and ERBB􀀅 amplification. We observed no differences in immune biomarkers such as PD-L1 expression and tumor mutational burden comparing CCNE􀀂-amplified and nonamplified tumors, although CCNE􀀂 amplification was associated with changes in immune populations such  \nas decreased B cells and increased M1 macrophages from transcriptional analysis. Real-world survival analysis demonstrated that patients with CCNE􀀂-amplified gastric cancer had worse survival after trastuzumab for HER2-positive tumors, but better survival after immunotherapy. These data suggest that CCNE􀀂-amplified gastric cancer has a distinct molecular and immune profile with important therapeutic implications, and therefore further investigation of CCNE􀀂 amplification as a predictive biomarker is warranted.  \nSignificance: Advanced gastric cancer has a relatively dismal outcome with a 5-year overall survival of less than 10% . Furthermore, while comprehensive molecular analyses have established molecular subtypes within gastric cancers, biomarkers of clinical relevance in this cancer type are lacking. Overall, this study demonstrates that CCNE􀀂 amplification is associated with a distinct molecular profile in gastric cancer and may impact response to therapy, including targeted therapy and/or immunotherapy.  \nIntroduction  \nGastric adenocarcinoma is one of the most common cancers worldwide, with over 1 million new diagnoses and 700,000 deaths annually (1, 2) . Comprehensive molecular analyses have identified key genetic alterations in gastric cancer and defined four molecular subtypes: genomically stable (GS), chro-  \n1 Department of Surgery, Division of Surgical Sciences, Columbia University Irving Medical Center, New York, New York. 2 Caris Life Sciences, Phoenix, Arizona.  \n3 Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota. 4 Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. 5 Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.  \n6 Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York.  \nCorresponding Author: Ryan H. Moy, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY 10024 . E-mail: [rhm2147@cumc.columbia.edu](rhm2147@cumc.columbia.edu)  \n[doi:](doi: 10.1158/2767-9764.CRC-23-0496)[ 10.1158/2767-9764.CRC-23-0496](doi: 10.1158/2767-9764.CRC-23-0496)  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4 .0) license.  \n© 2024 The Authors; Published by the American Asso","cbCaip02RjHIJGQA","https://ap.wps.com/l/cbCaip02RjHIJGQA","pdf",3125510,11,"English","# Abstract\n# Introduction\n## Gastric adenocarcinoma molecular subtypes and current biomarkers\n## CCNE1 amplification and potential therapeutic relevance\n## Study rationale and profiling approach","[{\"question\":\"How was CCNE1 amplification assessed in esophagogastric tumors in this study?\",\"answer\":\"The study integrated genomic, transcriptomic, and immune profiling analyses across 7,083 esophagogastric tumors to evaluate CCNE1 amplification and its associations with molecular features and outcomes.\"},{\"question\":\"Which tumor types showed CCNE1 amplification, and how common was it?\",\"answer\":\"CCNE1 amplification was reported in 6.2% of esophageal adenocarcinoma samples, 7.0% of esophagogastric junction carcinoma, 4.2% of gastric adenocarcinoma, and 0.8% of esophageal squamous cell carcinoma.\"},{\"question\":\"What immune-related differences were found between CCNE1-amplified and nonamplified tumors?\",\"answer\":\"Although PD-L1 expression and tumor mutational burden did not differ, transcriptional immune profiling associated CCNE1 amplification with decreased B cells and increased M1 macrophages.\"},{\"question\":\"How did CCNE1 amplification relate to survival after different treatments?\",\"answer\":\"Real-world survival analysis indicated worse survival after trastuzumab for HER2-positive tumors in patients with CCNE1-amplified gastric cancer, but better survival after immunotherapy.\"}]","Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer | PDF",1790020702,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a4eb5c2b859fc6a03354781f30d319c.webp",983,1263,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ecb79dcc5fd5e9f535f71a15f3bf3d0.webp",982,1262,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b584e599cae4d55aac30d6813f87d786.webp",981,1261,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fee857b942458c4b9b42f2a23b454704.webp",980,1259]